U.S. markets closed
  • S&P Futures

    3,836.50
    +8.50 (+0.22%)
     
  • Dow Futures

    31,402.00
    +31.00 (+0.10%)
     
  • Nasdaq Futures

    12,828.75
    -3.00 (-0.02%)
     
  • Russell 2000 Futures

    2,192.00
    -8.00 (-0.36%)
     
  • Crude Oil

    63.14
    -0.39 (-0.61%)
     
  • Gold

    1,771.40
    -4.00 (-0.23%)
     
  • Silver

    27.42
    -0.26 (-0.96%)
     
  • EUR/USD

    1.2176
    -0.0010 (-0.09%)
     
  • 10-Yr Bond

    1.5180
    +0.1290 (+9.29%)
     
  • Vix

    28.89
    +7.55 (+35.38%)
     
  • GBP/USD

    1.4011
    -0.0002 (-0.01%)
     
  • USD/JPY

    105.9720
    -0.2580 (-0.24%)
     
  • BTC-USD

    47,469.02
    -3,115.36 (-6.16%)
     
  • CMC Crypto 200

    944.50
    -50.16 (-5.04%)
     
  • FTSE 100

    6,651.96
    -7.01 (-0.11%)
     
  • Nikkei 225

    29,446.17
    -722.10 (-2.39%)
     

Terns to Present at the Cowen 41st Annual Health Care Conference

  • Oops!
    Something went wrong.
    Please try again later.
Terns Pharmaceuticals, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

FOSTER CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be presenting at the Cowen 41st Annual Health Care Conference on Thursday, March 4 at 9:50 a.m. ET.

A live audio webcast of the presentation will be available here and on Terns’ website at http://ir.ternspharma.com/. A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

Terns will also participate in a NASH panel at the conference on Tuesday, March 2 from 12:50-1:50 p.m. ET.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. For more information, please visit www.ternspharma.com.

US Media Contact:
Investor Relations Contact:
Mark Vignola
investors@ternspharma.com

Media Contact:
Cory Tromblee
media@ternspharma.com